公开(公告)号：US5972886A

公开(公告)日：1999-10-26

申请号：US611977

申请日：1996-03-06

申请人： Masafumi Tsujimoto ,  Fuyuki Iwasa ,  Nobuo Tsuruoka ,  Hiroshi Nakazato ,  Kenju Miura ,  Nobuhiro Ishida ,  Tatsuya Kurihara ,  Kozo Yamaichi ,  Nozomi Yamaguchi

发明人： Masafumi Tsujimoto ,  Fuyuki Iwasa ,  Nobuo Tsuruoka ,  Hiroshi Nakazato ,  Kenju Miura ,  Nobuhiro Ishida ,  Tatsuya Kurihara ,  Kozo Yamaichi ,  Nozomi Yamaguchi

IPC分类号： A61K38/00 ,  A61K38/19 ,  A61P7/00 ,  C07K1/20 ,  C07K14/00 ,  C07K14/47 ,  C07K14/475 ,  C07K16/22 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12N15/18 ,  C12N15/19 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  C07K14/52 ,  A61K38/18

CPC分类号： C07K14/475 ,  A61K38/00

摘要： A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host.The megakaryocyte differentiation factor accelerates differentiation of megakaryocytes in the presence of IL-3, and acts as a thrombopoietin, and therefore an effective medicament to various diseases involving a decrease in platelete.

公开(公告)号：US5831030A

公开(公告)日：1998-11-03

申请号：US472659

申请日：1995-06-07

申请人： Masafumi Tsujimoto ,  Fuyuki Iwasa ,  Nobuo Tsuruoka ,  Hiroshi Nakazato ,  Kenju Miura ,  Nobuhiro Ishida ,  Tatsuya Kurihara ,  Kozo Yamaichi ,  Nozomi Yamaguchi

发明人： Masafumi Tsujimoto ,  Fuyuki Iwasa ,  Nobuo Tsuruoka ,  Hiroshi Nakazato ,  Kenju Miura ,  Nobuhiro Ishida ,  Tatsuya Kurihara ,  Kozo Yamaichi ,  Nozomi Yamaguchi

IPC分类号： A61K38/00 ,  A61K38/19 ,  A61P7/00 ,  C07K1/20 ,  C07K14/00 ,  C07K14/47 ,  C07K14/475 ,  C07K16/22 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12N15/18 ,  C12N15/19 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91

CPC分类号： C07K14/475 ,  A61K38/00

摘要： The present invention provides novel megakaryocyte differentiation factors, which are useful as therapeutic agents due to their accelerating effects on the differentiation of megakaryocytes and their thrombopoietic effects. The megakaryocyte differentiation factors of the present invention include the megakaryocyte differentiation factor having the amino acid sequence shown in SEQ ID NO: 34. The present invention also provides DNA coding for the megakaryocyte differentiation factors of the present invention, expression vectors containing the DNA, hosts transformed with the expression vectors, and processes for production of the megakaryocyte differentiation factors using transformed hosts. The present invention further provides specific antibodies to the megakaryocyte differentiation factors of the present invention.

摘要翻译： 本发明提供了新的巨核细胞分化因子，由于它们对巨核细胞的分化及其血小板生成作用的加速作用，它们可用作治疗剂。 本发明的巨核细胞分化因子包括具有SEQ ID NO：34所示的氨基酸序列的巨核细胞分化因子。本发明还提供编码本发明的巨核细胞分化因子的DNA，含有该DNA的表达载体，宿主 用表达载体转化，以及使用转化宿主生产巨核细胞分化因子的过程。 本发明还提供了针对本发明的巨核细胞分化因子的特异性抗体。

公开(公告)号：US5874253A

公开(公告)日：1999-02-23

申请号：US474661

申请日：1995-06-07

申请人： Masafumi Tsujimoto ,  Fuyuki Iwasa ,  Nobuo Tsuruoka ,  Hiroshi Nakazato ,  Kenju Miura ,  Nobuhiro Ishida ,  Tatsuya Kurihara ,  Kozo Yamaichi ,  Nozomi Yamaguchi

发明人： Masafumi Tsujimoto ,  Fuyuki Iwasa ,  Nobuo Tsuruoka ,  Hiroshi Nakazato ,  Kenju Miura ,  Nobuhiro Ishida ,  Tatsuya Kurihara ,  Kozo Yamaichi ,  Nozomi Yamaguchi

IPC分类号： A61K38/00 ,  A61K38/19 ,  A61P7/00 ,  C07K1/20 ,  C07K14/00 ,  C07K14/47 ,  C07K14/475 ,  C07K16/22 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12N15/18 ,  C12N15/19 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  C12P21/06 ,  C07H21/04 ,  C12N5/00 ,  C12N15/00

CPC分类号： C07K14/475 ,  A61K38/00

摘要： A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host. The megakaryocyte differentiation factor accelerates differentiation of megakaryocytes in the presence of IL-3, and acts as a thrombopoietin, and therefore an effective medicament to various diseases involving a decrease in platelete.

摘要翻译： 一种新型巨核细胞分化因子，例如基本上由SEQ ID NO：30组成; 编码巨核细胞分化因子的DNA，包含DNA的表达载体，用表达载体转化的宿主以及使用该宿主产生巨核细胞分化因子的方法。 巨核细胞分化因子加速了在IL-3存在下巨核细胞的分化，并且作为血小板生成素，因此是涉及减少血小板的各种疾病的有效药物。

公开(公告)号：US4820641A

公开(公告)日：1989-04-11

申请号：US749564

申请日：1985-06-27

申请人： Toshihiro Nakanishi ,  Yoshiaki Fukuda ,  Kenju Miura ,  Hiroshi Nakazato

发明人： Toshihiro Nakanishi ,  Yoshiaki Fukuda ,  Kenju Miura ,  Hiroshi Nakazato

IPC分类号： G01N33/574 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/005 ,  C07K14/195 ,  C07K16/00 ,  C07K16/30 ,  C12N5/02 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/577 ,  C12N5/00 ,  C07K15/04

CPC分类号： C07K16/3038 ,  A61K38/00 ,  C07K2317/732

摘要： The specification discloses a monoclonal antibody capable of distinguishing human hepato-carcinoma cells, a hybridoma producing said monoclonal antibody and a process for preparing the monoclonal antibody using said hybridoma. The monoclonal antibody of the invention specifically attackes hepato-carcinoma cells in vivo.

摘要翻译： 该说明书公开了能够区分人肝癌细胞的单克隆抗体，产生所述单克隆抗体的杂交瘤和使用所述杂交瘤制备单克隆抗体的方法。 本发明的单克隆抗体体内特异性侵袭肝癌细胞。

公开(公告)号：US07282201B2

公开(公告)日：2007-10-16

申请号：US10649952

申请日：2003-08-28

申请人： Kenju Miura ,  Munetada Haruyama ,  Shiho Kodama

发明人： Kenju Miura ,  Munetada Haruyama ,  Shiho Kodama

IPC分类号： A61K35/14 ,  A61K38/18 ,  A61K38/19 ,  C07K14/435 ,  C07K14/475 ,  C07K14/52 ,  C12N5/00

CPC分类号： A61K38/18 ,  A61K38/1709 ,  A61K38/202 ,  A61K2300/00

摘要： This invention has as its object providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors which are useful as therapeutics of diseases that result from insufficient growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors, in particular, as therapeutics of panhematopenia and/or diseases that are accompanied by hematopoietic hypofunction. The invention attains the stated object by providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors that contain Cofilin as an active ingredient.

摘要翻译： 本发明的目的在于提供造血干细胞和/或造血祖细胞的生长和/或分化的启动子，其可用作由造血干细胞和/或造血祖细胞的生长和/或分化不足引起的疾病的治疗剂， 特别是作为伴有造血功能减退症的全血象减少症和/或疾病的治疗剂。 本发明通过提供含有Cofilin作为活性成分的造血干细胞和/或造血祖细胞的生长和/或分化的启动子达到上述目的。

公开(公告)号：US5126253A

公开(公告)日：1992-06-30

申请号：US912678

申请日：1986-09-25

申请人： Toshihiro Nakanishi ,  Masashi Matsui ,  Kenju Miura ,  Yoshiaki Fukuda ,  Teruhisa Noguchi

发明人： Toshihiro Nakanishi ,  Masashi Matsui ,  Kenju Miura ,  Yoshiaki Fukuda ,  Teruhisa Noguchi

IPC分类号： C07K14/52 ,  C07K14/57 ,  C12N5/02 ,  C12N5/16 ,  C12P21/08

CPC分类号： C12N5/163 ,  C07K14/52 ,  C07K14/57 ,  Y10S435/948

摘要： A novel cell line for use as a parent for hybridoma preparation is provided. This cell line is derived from tumor cells, in particular human tumor cells, other than those originating from bone marrow cells. A method for establishing this cell line is also provided. By fusing this cell line with cells producing useful physiologically active substances, such as B cells immunized with an antigen, a hybridoma capable of active growth can be prepared. This hybridoma can be cultivated for the production of useful physiologically active substances.

摘要翻译： 提供了用作杂交瘤制备的亲本的新型细胞系。 该细胞系来自肿瘤细胞，特别是源于骨髓细胞的肿瘤细胞。 还提供了建立该细胞系的方法。 通过将该细胞系与产生有用的生理活性物质的细胞（例如用抗原免疫的B细胞）融合，可以制备能够活跃生长的杂交瘤。 该杂交瘤可用于生产有用的生理活性物质。

公开(公告)号：US6040335A

公开(公告)日：2000-03-21

申请号：US849887

申请日：1997-07-31

申请人： Masayuki Saitoh ,  Yasuo Kitajima ,  Norio Iwasawa ,  Kenju Miura ,  Munetada Haruyama ,  Junko Hashino

发明人： Masayuki Saitoh ,  Yasuo Kitajima ,  Norio Iwasawa ,  Kenju Miura ,  Munetada Haruyama ,  Junko Hashino

IPC分类号： C07F9/655 ,  A61K31/365 ,  C07D309/02

CPC分类号： C07F9/6552

摘要： Compounds represented by the general formula (I) or pharmacologically acceptable salts thereof: ##STR1## (where R is a group --NHCHR.sub.1 R.sub.2, --N(CHR.sub.1 R.sub.2).sub.2, --N(CHR.sub.1 R.sub.2)CHR.sub.3 R.sub.4, --N.sup.+ (CHR.sub.1 R.sub.2).sub.3, --N.sup.+ (CHR.sub.1 R.sub.2).sub.2 CHR.sub.3 R.sub.4 or --N.sup.+ (CHR.sub.1 R.sub.2)(CHR.sub.3 R.sub.4)CHR.sub.5 R.sub.6 (where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6, which may be the same or different, are each a hydrogen atom, an alkyl group, an alkenyl group, an aryl group or an aralkyl group, or an alkyl, alkenyl, aryl or aralkyl group which is substituted by at least one substituent selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a lower alkylacyloxy group, a lower alkylacyl group, a lower alkoxycarbonyl group, a nitro group, a cyano group and a heterocyclic group, with CHR.sub.1 R.sub.2, CHR.sub.3 R.sub.4 or CHR.sub.5 R.sub.6 optionally forming a cyclic alkyl group, provided that when R is --N(CHR.sub.1 R.sub.2)CHR.sub.3 R.sub.4, --N.sup.+ (CHR.sub.1 R.sub.2).sub.2 CHR.sub.3 R.sub.4 or --N.sup.+ (CHR.sub.1 R.sub.2)(CHR.sub.3 R.sub.4)CHR.sub.5 R.sub.6, CHR.sub.1 R.sub.2, CHR.sub.3 R.sub.4 and CHR.sub.5 R.sub.6 are different groups); therapeutics for thrombocytopenia containing them as an effective ingredient; as well as intermediates for their synthesis and processes for producing them.

摘要翻译： PCT No.PCT / JP96 / 03008 Sec。 371日期1997年7月31日 102（e）1997年7月31日PCT PCT 1996年10月17日PCT公布。 出版物WO97 / 14704 日期：1997年04月24日由通式（I）表示的化合物或其药理学上可接受的盐：（其中R为基团-NHCHR1R2，-N（CHR1R2）2，-N（CHR1R2）CHR3R4，-N +（CHR1R2） -N +（CHR 1 R 2）2 CHR 3 R 4或-N +（CHR 1 R 2）（CHR 3 R 4）CHR 5 R 6（其中R 1，R 2，R 3，R 4，R 5和R 6可以相同或不同，分别为氢原子，烷基， 基团，芳基或芳烷基，或被选自卤素原子，羟基，低级烷氧基，低级烷基酰氧基中的至少一个取代基取代的烷基，烯基，芳基或芳烷基 基团，低级烷基酰基，低级烷氧基羰基，硝基，氰基和杂环基，与任选形成环状烷基的CHR 1 R 2，CHR 3 R 4或CHR 5 R 6，条件是当R为-N（CHR 1 R 2）CHR 3 R 4时， N +（CHR1R2）2CHR3R4或-N +（CHR1R2）（CHR3R4）CHR5R6，CHR1R2，CHR3R4和CHR5R6是不同的组）;含有血小板减少症的治疗剂 有益成分; 以及它们的合成中间体及其制备方法。